ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing cancer medicines that overcome resistance mechanisms in oncology. The company advances a pipeline of precision oncology therapies targeting hormone-dependent cancers, including its lead programs rinzimetostat, an allosteric PRC2 inhibitor for metastatic castration-resistant prostate cancer, and enozertinib, a brain-penetrant EGFR inhibitor for non-small cell lung cancer with exon 20 mutations, both licensed from external partners. ORIC generates no revenue from product sales but pursues a strategy of advancing its programs through clinical development stages in collaboration with major pharmaceutical partners including Johnson & Johnson and Bayer, with the intention to build commercial infrastructure in the United States and select regions if its candidates advance successfully.